Ken Griffin Bluebird Bio, Inc. Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bluebird Bio, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 122,400 shares of BLUE stock, worth $112,608. This represents 0.0% of its overall portfolio holdings.
Number of Shares
122,400
Previous 403,500
69.67%
Holding current value
$112,608
Previous $556,000
71.94%
% of portfolio
0.0%
Previous 0.0%
Shares
26 transactions
Others Institutions Holding BLUE
# of Institutions
173Shares Held
104MCall Options Held
827KPut Options Held
1.23M-
Black Rock Inc. New York, NY15.2MShares$14 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.5MShares$9.66 Million0.0% of portfolio
-
Granahan Investment Management, LLC Waltham, MA7.71MShares$7.09 Million0.35% of portfolio
-
Ameriprise Financial Inc Minneapolis, MN6.39MShares$5.88 Million0.0% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny6.24MShares$5.74 Million0.0% of portfolio
About bluebird bio, Inc.
- Ticker BLUE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 77,121,800
- Market Cap $71M
- Description
- bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...